Prilenia Therapeutics
A Clinical Stage Biotech Company
Amsterdam, Netherlands · Founded 2018 · $115.5M raised
- Headquarters
- Amsterdam
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- prilenia.com
- Total Funding
- $115.5M
- Last Round
- $10.0M Series BJan 2022
- Rounds
- 3
About
Clinical-stage biotech developing novel therapeutics to slow progression of neurodegenerative diseases including Huntington's disease and ALS.
Summary
Prilenia Therapeutics is a Biotech company based in Amsterdam, Netherlands, founded in 2018. It has raised $115.5M in total across 3 rounds, most recently a $10.0M Series B round in Jan 2022. Investors include Forbion Capital Partners, Sands Capital and Sectoral Asset Management.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2022
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company